PRP28 Antibody

What is Prp28 and why is it important in splicing research?

Prp28 is a DEAD-box ATPase that serves dual critical functions in pre-mRNA splicing. Its primary characterized role is promoting the displacement of U1 snRNP from the intron 5' splice site during spliceosome activation, which requires ATP hydrolysis. More recently, researchers have discovered that Prp28 also has an earlier, ATP-independent function in splicing complex formation, specifically in commitment complex 2 (CC2) assembly . These dual functions make Prp28 an essential protein for understanding spliceosome dynamics and assembly pathways. Prp28 antibodies are therefore crucial tools for investigating these processes, enabling immunoprecipitation experiments, western blotting, and immunolocalization studies that help elucidate the temporal and spatial dynamics of splicing complex formation.

How do yeast and human Prp28 proteins differ structurally and functionally?

Yeast Prp28 differs structurally from its human counterpart (hPrp28) in several significant ways. Most notably, yeast Prp28 lacks the metazoan-specific N-terminal region present in human Prp28, which can be phosphorylated and serves as an anchor to the human spliceosome . Additionally, yeast Prp28 exists primarily in free form rather than as an integrated component of U5-snRNP like its human counterpart . Despite these structural differences, both proteins share the core functional characteristic of exhibiting negligible ATPase activity when purified, suggesting they both require activation by cofactors or the spliceosomal environment . When designing experiments with Prp28 antibodies, researchers should consider these species-specific differences, particularly when attempting to extrapolate findings between yeast and human systems.

What are the recommended applications for Prp28 antibodies in splicing research?

Prp28 antibodies have proven particularly valuable in several experimental approaches investigating spliceosome assembly and dynamics. Key applications include:

• Immunoprecipitation: Prp28 antibodies can effectively co-precipitate splicing complexes, as demonstrated in studies where the amount of pre-mRNA co-precipitated by anti-Prp28 antibody peaked at specific ATP concentrations (0.05 mM) . This approach allows isolation of distinct splicing complexes at different assembly stages.

• Western blotting: Critical for confirming cross-linking results and protein interactions, as shown in experiments that identified Prp8 as a Prp28-interacting partner through initial mass spectrometry followed by immunoblotting verification with anti-Prp8 and anti-Prp28 antibodies .

• Protein-RNA interaction studies: In combination with UV cross-linking (254 nm), Prp28 antibodies enable the immunoprecipitation of cross-linked RNA under denaturing conditions, allowing researchers to map precise contact points between Prp28 and pre-mRNA, such as the highly conserved GU dinucleotide at the 5′SS .

• Spliceosome assembly analysis: Prp28 antibodies help track the protein throughout the splicing reaction, revealing its dynamic association with specific complexes at different ATP concentrations and assembly stages.

How should researchers optimize Prp28 antibody-based immunoprecipitation of splicing complexes?

Optimizing Prp28 antibody-based immunoprecipitation requires careful attention to several experimental parameters:

• ATP concentration: The critical factor affecting Prp28's association with splicing complexes is ATP concentration. Research has demonstrated that the amount of pre-mRNA co-precipitated by anti-Prp28 antibody peaks at 0.05 mM ATP . Therefore, researchers should consider using ATP titration (0.02-2 mM range) when studying different stages of spliceosome assembly.

• Cross-linking conditions: When investigating Prp28's interactions with other spliceosomal components, UV irradiation conditions should be standardized. For RNA-protein cross-linking, 254 nm UV light works effectively, while protein-protein cross-linking may employ BPA (p-benzoyl-phenylalanine) incorporation at specific residues followed by 365 nm UV irradiation .

• RNase treatment controls: Including RNase A treatment after UV irradiation but before immunoprecipitation serves as an important control to distinguish direct protein-protein interactions from RNA-mediated associations. In published studies, RNase treatment did not abolish certain cross-linking signals, confirming direct protein contacts .

• Antibody specificity verification: Before conducting extensive experiments, researchers should confirm the specificity of their Prp28 antibody through western blotting against both wild-type extracts and extracts from strains with tagged Prp28 or Prp28 mutants.

By attending to these parameters, researchers can effectively isolate specific Prp28-containing complexes and accurately characterize Prp28's dynamic interactions during splicing.

What methods can be used to assess Prp28's ATPase activity and its regulation?

Measuring Prp28's ATPase activity presents particular challenges since both purified yeast Prp28 and human Prp28 exhibit negligible intrinsic ATPase activity in vitro . To effectively study Prp28's ATPase function, researchers should consider:

• RNA-dependence assays: Recent research has established that yeast Prp28 is a bona fide RNA-dependent ATPase, albeit with a low turnover number . Experimental designs should include RNA titration (0-5 μg/μl yeast RNA type III) when measuring ATP hydrolysis.

• Time-course measurements: Given Prp28's low ATPase activity, extended incubation times (up to 9 hours) at 37°C with sampling at regular intervals allows detection of cumulative ADP production .

• Cofactor assessment: Testing potential cofactors is critical, particularly phosphorylated Npl3, which has been shown to potentiate Prp28's ATPase activity . Control experiments should include both phosphorylated and unphosphorylated Npl3 to demonstrate specificity.

• Detection methods: HPLC analysis of reaction mixtures provides sensitive detection of ADP production. Samples should be heat-treated (85°C for 2 min) to inactivate the enzyme and precipitate protein before centrifugation and loading onto a reversed-phase HPLC column .

A complete experimental setup should include negative controls (reaction mixture without Prp28) and positive controls (a known DEAD-box helicase with robust ATPase activity). This methodological approach allows for reliable assessment of factors that regulate Prp28's enzymatic function.

How can researchers implement BPA-mediated cross-linking to map Prp28's interactions within the spliceosome?

BPA (p-benzoyl-phenylalanine)-mediated cross-linking represents a sophisticated approach for capturing transient protein-protein interactions of Prp28 within the dynamic spliceosomal environment. To implement this technique effectively:

• Strategic residue selection: Researchers should select surface-exposed, non-conserved hydrophilic residues for BPA replacement, as these are less likely to disrupt Prp28's core function. Computational modeling based on related DEAD-box protein structures (e.g., Vasa) can guide selection . Studies have successfully incorporated BPA at positions K27, K41, K82, and K136 in yeast Prp28 .

• Genetic incorporation system: The experimental system requires an orthogonal pair of aminoacyl tRNA synthetase and suppressor tRNA (UAG) for in vivo BPA incorporation. Researchers must first construct PRP28 alleles containing UAG stop codons at the desired positions and verify that these alleles support cell growth in BPA-containing media .

• Functional verification: Before proceeding with cross-linking experiments, researchers should confirm that the BPA-incorporated Prp28 variants remain functional. This can be assessed by testing whether the engineered strains produce active splicing extracts .

• Cross-linking conditions optimization: Cross-linking should be performed in active splicing reactions with optimal ATP concentrations (0.02-2 mM range) and controlled UV irradiation (365 nm). Essential controls include reactions without pre-mRNA, with mutated splice sites, and without UV irradiation .

• Cross-linked product analysis: Initial analysis by SDS-PAGE and immunoblotting can identify cross-linked species, followed by scaled-up reactions and mass spectrometry for precise identification of interacting partners. In previous studies, this approach successfully identified interactions with Prp8, Brr2, Snu114, and U1C .

This technique has revealed that Prp28 makes extensive contacts with U5 snRNP components even before stable tri-snRNP integration into the spliceosome, providing insights into previously uncharacterized early functions of Prp28.

What approaches can be used to study the functional relationship between Prp28 and Prp8?

Investigating the functional relationship between Prp28 and Prp8 requires a multi-faceted approach combining genetic, biochemical, and structural methods:

• Genetic interaction analysis: Systematic testing of synthetic genetic interactions between PRP28 and PRP8 mutant alleles has proven highly informative. For example, researchers identified that mutations in Prp8's N-terminal bromodomain-like sequence suppress the cold-sensitive phenotype of prp28-1 . A methodical approach includes:

  • Creating a panel of PRP8 mutants through error-prone PCR or site-directed mutagenesis targeting specific domains

  • Testing these against PRP28 mutants in various conditions (temperature, splicing reporters)

  • Quantifying growth phenotypes to determine suppression strength

• Domain mapping: Targeted mutagenesis of specific Prp8 regions has identified the N-terminal domain (residues 222-314) as particularly important for interaction with Prp28 . When studying new potential interaction sites, researchers should create single amino acid substitutions at multiple positions and assess their individual and combinatorial effects.

• Specificity testing: To determine whether suppressor mutations in Prp8 specifically affect Prp28 function or have broader effects on splicing, suppressors should be tested against other splicing mutants (e.g., U4-cs1, brr2-1) . True specificity would be indicated by suppression of only Prp28-related defects.

• Biochemical interaction analysis: Using purified components or extracts from genetically modified strains, researchers can assess:

  • Direct interactions using pull-down assays with tagged proteins

  • Conformational effects using limited proteolysis

  • Functional consequences through in vitro splicing assays with wild-type and mutant components

These approaches collectively provide a comprehensive understanding of how Prp8, particularly its N-terminal region, influences both the ATP-independent and ATP-dependent functions of Prp28 during spliceosome assembly and activation.

How should researchers interpret conflicting data between yeast and human Prp28 studies?

When confronted with apparently contradictory results between yeast and human Prp28 studies, researchers should systematically evaluate several factors:

• Structural differences analysis: The absence of the metazoan-specific N-terminal region in yeast Prp28 represents a fundamental difference that may explain functional variations . When interpreting conflicting data, researchers should specifically consider whether the observed differences might relate to:

  • Phosphorylation-dependent regulation (present in human, absent in yeast)

  • Association with U5-snRNP (stable in human, transient in yeast)

  • Protein-protein interaction networks specific to each system

• Experimental condition variations: Different ATP concentrations dramatically affect Prp28's interactions and functions. For example, Prp28's contact with pre-mRNA peaks at 0.05 mM ATP in yeast systems . Researchers should carefully compare ATP concentrations, salt conditions, and reaction temperatures when evaluating conflicting reports.

• Contact point mapping discrepancies: Studies mapping Prp28's RNA contacts have shown differences between yeast and human systems. While yeast Prp28 contacts the GU dinucleotide at the 5′SS, human Prp28 predominantly contacts the +7 position downstream of the 5′SS consensus . These differences may reflect genuine evolutionary divergence in mechanism rather than experimental error.

• Functional conservation testing: To resolve conflicts, researchers can perform cross-species complementation experiments, introducing human PRP28 into yeast prp28Δ strains with appropriate controls for expression levels and localization. Partial or conditional complementation would suggest conserved core functions with species-specific adaptations.

Through this systematic evaluation approach, apparent contradictions can often be reconciled as reflections of evolutionary specialization rather than experimental inconsistencies.

What controls are essential when using Prp28 antibodies to study spliceosome dynamics?

When using Prp28 antibodies for investigating spliceosome assembly and dynamics, researchers must implement a comprehensive set of controls:

• Specificity controls:

  • Western blotting against extracts from wild-type and prp28Δ strains (where viable) or conditional mutants

  • Comparison of results using multiple antibodies targeting different Prp28 epitopes

  • Pre-absorption of antibodies with purified recombinant Prp28 to confirm signal reduction

• Functional RNA controls:

  • Inclusion of pre-mRNA with mutations in the 5′SS and branch site, which should disrupt Prp28-dependent splicing complex formation

  • Use of intronless RNA as a negative control

  • RNase treatment after cross-linking but before immunoprecipitation to distinguish RNA-mediated from direct protein interactions

• ATP-dependence controls:

  • Parallel experiments with ATP, ATP analogs (AMP-PNP), and ATP-depleted conditions

  • ATP titration series (0.02-2 mM) to capture the complete profile of Prp28's dynamic interactions

  • Addition of phosphatase inhibitors when studying phosphorylation-dependent interactions

• Cross-linking controls:

  • Omission of UV irradiation in parallel samples

  • Dose-dependent UV exposure series

  • BPA-free controls when using BPA-mediated cross-linking

• Antibody performance validation:

  • Regular testing of antibody lots for consistent performance

  • Side-by-side comparison with epitope-tagged Prp28 detected via tag-specific antibodies

  • Titration experiments to ensure antibody excess conditions

Implementation of these controls ensures that observed signals truly represent specific Prp28 interactions rather than experimental artifacts, enabling confident interpretation of complex spliceosomal dynamics data.

How does phosphorylated Npl3 regulate Prp28's ATPase activity and what are the implications for experimental design?

Recent research has revealed that phosphorylated Npl3 serves as a critical regulator of Prp28's ATPase activity, providing important insights into the regulation of DEAD-box helicases in the spliceosome. The mechanistic details and experimental implications include:

• Specificity of activation: Prp28's ATPase activity is specifically potentiated by phosphorylated Npl3, while unphosphorylated Npl3 fails to activate the enzyme . This phosphorylation-dependent regulation represents a novel strategy for controlling DEAD/H-box ATPases in the splicing process. When designing experiments to study Prp28's enzymatic activity, researchers must control the phosphorylation state of any Npl3 present in the reaction.

• Functional homology with metazoan systems: The phosphorylated Npl3 appears to serve as a functional counterpart to the metazoan-specific N-terminal region of human Prp28, which can also be phosphorylated . This suggests evolutionary conservation of regulatory mechanisms despite structural divergence. Cross-species complementation experiments with phosphomimetic mutations could test this functional equivalence hypothesis.

• Experimental approaches to study this regulation:

  • In vitro ATPase assays comparing reactions with phosphorylated versus unphosphorylated Npl3

  • Phosphorylation site mapping in Npl3 using mass spectrometry

  • Creation of phosphomimetic (Ser/Thr to Asp/Glu) and phospho-deficient (Ser/Thr to Ala) Npl3 mutants

  • Cross-linking studies to map the interaction interface between Prp28 and phosphorylated Npl3

• Implications for spliceosome regulation: This discovery suggests that phosphorylation events may coordinate the timing of Prp28 activation within the spliceosome. Researchers studying spliceosome dynamics should consider monitoring the phosphorylation status of Npl3 alongside Prp28 activity to understand this regulatory relationship.

Understanding this regulatory mechanism provides a framework for investigating similar phosphorylation-dependent control of other spliceosomal ATPases, potentially revealing common principles in spliceosome regulation.

What research directions are emerging for studying Prp28's dual roles in spliceosome assembly and activation?

The discovery that Prp28 has both ATP-independent and ATP-dependent functions in splicing has opened several promising research directions:

• Structural investigation of Prp28's different functional states:

  • Crystal structures of Prp28 in different nucleotide-bound states (apo, ADP, ATP) would reveal conformational changes associated with its dual functions

  • Cryo-EM studies of Prp28 within early splicing complexes (commitment complexes) versus later pre-catalytic spliceosomes

  • Hydrogen-deuterium exchange mass spectrometry to map conformational dynamics during different functional states

• Mechanistic dissection of ATP-independent versus ATP-dependent functions:

  • Engineering of separation-of-function mutations that specifically affect only one of Prp28's dual roles

  • Time-resolved cross-linking studies to track Prp28's changing interaction network during the transition from commitment complex to pre-catalytic spliceosome

  • Single-molecule approaches to directly visualize Prp28's contributions to early complex assembly versus later remodeling events

• Coordination with other spliceosomal components:

  • Investigation of how Prp8's N-terminal bromodomain-like region influences both the ATP-independent and ATP-dependent functions of Prp28

  • Exploration of potential connections between Prp28 activity and other ATPases (particularly Brr2), given the evidence that mutations affecting either Prp28 or Brr2 function block both U1 and U4 release

  • Systematic testing of genetic interactions between PRP28 and other splicing factors to build a comprehensive functional interaction network

• Regulation and coordination of Prp28's dual activities:

  • Investigation of how phosphorylation of Npl3 might differentially affect Prp28's early versus late functions

  • Identification of additional cofactors that might specifically regulate one of Prp28's dual roles

  • Studies of how Prp28's functions might be modulated under cellular stress conditions